BEAM
Beam Therapeutics Inc. NASDAQ Listed Feb 6, 2020$31.48
Mkt Cap $3.2B
52w Low $15.35
76.5% of range
52w High $36.44
50d MA $27.30
200d MA $25.18
P/E (TTM)
-37.9x
EV/EBITDA
-91.6x
P/B
2.5x
Debt/Equity
0.2x
ROE
-6.5%
P/FCF
-7.6x
RSI (14)
—
ATR (14)
—
Beta
2.19
50d MA
$27.30
200d MA
$25.18
Avg Volume
2.0M
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
238 Main Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 32.34 | -1.9% | -2.7% | — | — | — | — | — |
| Feb 24, 2026 | BMO | -1.13 | -0.10 | +91.2% | 32.29 | +2.2% | -8.3% | -8.3% | -10.4% | -11.9% | -11.1% | — |
| Nov 4, 2025 | BMO | -0.98 | -1.10 | -12.2% | 22.74 | +1.0% | +1.5% | +1.5% | +1.8% | -2.3% | -4.8% | — |
| Aug 5, 2025 | BMO | -1.04 | -1.00 | +3.8% | 18.70 | -2.1% | -2.1% | -2.1% | -4.5% | -5.8% | -8.2% | — |
| May 6, 2025 | BMO | -1.11 | -1.24 | -11.7% | 15.99 | +1.3% | +1.5% | +1.5% | +7.9% | +8.9% | +14.1% | — |
| Feb 25, 2025 | BMO | -1.25 | -1.09 | +12.8% | 29.84 | -0.0% | -6.5% | -6.5% | -9.1% | -11.7% | -15.9% | — |
| Nov 5, 2024 | BMO | -1.13 | -1.17 | -3.5% | 23.93 | +8.7% | +11.2% | +11.2% | +9.1% | +13.1% | +26.8% | — |
| Aug 6, 2024 | BMO | -1.13 | -1.11 | +1.8% | 25.52 | -0.0% | -4.2% | -4.2% | -2.4% | -4.2% | -6.0% | — |
| May 7, 2024 | BMO | -1.45 | -1.21 | +16.6% | 22.53 | -3.6% | -1.3% | -1.3% | +0.0% | -5.6% | +6.6% | — |
| Feb 27, 2024 | BMO | -1.01 | 1.73 | +271.3% | 45.07 | -0.5% | -3.2% | -3.2% | -12.4% | -11.6% | -15.2% | — |
| Nov 8, 2023 | BMO | -1.37 | -1.22 | +10.9% | 22.90 | +1.2% | -3.0% | -3.0% | -3.2% | -4.2% | +7.2% | — |
| Aug 8, 2023 | BMO | -1.38 | -1.08 | +21.7% | 26.25 | +0.6% | -0.5% | -0.5% | -3.2% | -2.7% | -3.9% | — |
| May 10, 2023 | BMO | -1.36 | -1.33 | +2.2% | 35.85 | -0.8% | -1.9% | -1.9% | -7.0% | +0.4% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | Citigroup | Maintains | Buy → Buy | — | $23.12 | $23.15 | +0.1% | +2.2% | -4.0% | -5.3% | +3.1% | +4.8% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $32.29 | $33.00 | +2.2% | -8.3% | -10.4% | -11.9% | -11.1% | -15.7% |
| Feb 25 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $32.29 | $33.00 | +2.2% | -8.3% | -10.4% | -11.9% | -11.1% | -15.7% |
| Jan 21 | Bernstein | Maintains | Outperform → Outperform | — | $30.97 | $30.84 | -0.4% | +0.5% | +10.6% | +1.9% | -0.1% | -0.9% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.87 | $28.48 | +2.2% | -5.6% | -8.9% | -8.8% | -2.4% | -7.5% |
| Oct 9 | JP Morgan | Maintains | Overweight → Overweight | — | $27.00 | $27.15 | +0.6% | +3.2% | -2.5% | -6.0% | -5.9% | +0.7% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.60 | $20.88 | +1.4% | +3.3% | +11.2% | +9.0% | +21.8% | +18.1% |
| Aug 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $18.70 | $18.31 | -2.1% | -2.1% | -4.5% | -5.8% | -8.2% | -9.8% |
| May 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.99 | $16.20 | +1.3% | +1.5% | +7.9% | +8.9% | +14.1% | +12.9% |
| May 7 | Guggenheim | Maintains | Buy → Buy | — | $15.99 | $16.20 | +1.3% | +1.5% | +7.9% | +8.9% | +14.1% | +12.9% |
| May 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $15.99 | $16.20 | +1.3% | +1.5% | +7.9% | +8.9% | +14.1% | +12.9% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.27 | $14.51 | -5.0% | +0.2% | -4.8% | +7.2% | -4.2% | +1.3% |
| Mar 28 | BofA Securities | Upgrade | Neutral → Buy | — | $22.19 | $22.54 | +1.6% | +0.1% | -12.0% | -20.5% | -16.7% | -25.8% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.42 | $26.91 | +1.9% | +3.8% | -5.1% | -8.3% | -7.2% | -14.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.48 | $27.84 | -2.2% | -9.8% | -7.2% | -3.7% | -12.0% | -14.9% |
| Mar 10 | Jones Trading | Upgrade | Hold → Buy | — | $28.48 | $27.84 | -2.2% | -9.8% | -7.2% | -3.7% | -12.0% | -14.9% |
| Mar 10 | Scotiabank | Upgrade | Sector Perform → Sector Outperform | — | $28.48 | $27.84 | -2.2% | -9.8% | -7.2% | -3.7% | -12.0% | -14.9% |
| Mar 3 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $26.34 | $26.54 | +0.8% | -4.7% | +0.4% | -0.9% | +3.5% | +8.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.11 | $26.77 | -1.3% | -2.8% | -7.4% | -2.5% | -3.7% | +0.5% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $27.89 | $28.22 | +1.2% | -2.8% | -5.6% | -10.0% | -5.2% | -6.4% |
| Feb 26 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $29.84 | $29.83 | -0.0% | -6.5% | -9.1% | -11.7% | -15.9% | -11.4% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.92 | $25.02 | -3.5% | -1.3% | -0.7% | +7.3% | +6.7% | +5.7% |
| Jan 29 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $25.26 | $26.10 | +3.3% | +2.6% | +8.0% | +2.6% | +1.3% | +1.9% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.71 | $27.76 | +3.9% | +3.0% | +13.1% | +8.2% | +5.1% | +4.6% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.62 | $26.56 | -0.2% | -2.0% | +1.7% | +14.0% | +5.0% | +3.3% |
| Nov 6 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $23.93 | $26.00 | +8.7% | +11.2% | +9.1% | +13.1% | +26.8% | +16.8% |
| Nov 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $23.93 | $26.00 | +8.7% | +11.2% | +9.1% | +13.1% | +26.8% | +16.8% |
| Sep 19 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $25.51 | $26.66 | +4.5% | +2.1% | +0.5% | -3.1% | -2.9% | -4.0% |
| Sep 11 | Stifel | Maintains | Buy → Buy | — | $23.65 | $23.65 | +0.0% | +2.0% | +3.2% | +11.2% | +8.3% | +8.2% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.49 | $25.65 | +0.6% | -3.8% | +5.2% | +6.4% | +3.1% | +2.2% |
| Aug 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $25.52 | $25.51 | -0.0% | -4.2% | -2.4% | -4.2% | -6.0% | -4.6% |
| Aug 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $25.52 | $25.51 | -0.0% | -4.2% | -2.4% | -4.2% | -6.0% | -4.6% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $25.52 | $25.51 | -0.0% | -4.2% | -2.4% | -4.2% | -6.0% | -4.6% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $22.53 | $21.71 | -3.6% | -1.3% | +0.0% | -5.6% | +6.6% | +5.7% |
| Apr 23 | Wedbush | Maintains | Outperform → Outperform | — | $24.10 | $24.04 | -0.2% | -2.6% | -5.6% | -10.4% | -11.3% | -8.5% |
| Mar 27 | BMO Capital | Maintains | Outperform → Outperform | — | $33.22 | $33.56 | +1.0% | +2.2% | -0.5% | -1.7% | -8.0% | -10.7% |
| Feb 28 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $45.07 | $44.85 | -0.5% | -3.2% | -12.4% | -11.6% | -15.2% | -14.6% |
| Feb 28 | Barclays | Maintains | Equal Weight → Equal Weight | — | $45.07 | $44.85 | -0.5% | -3.2% | -12.4% | -11.6% | -15.2% | -14.6% |
| Jan 29 | JP Morgan | Upgrade | Neutral → Overweight | — | $24.29 | $26.05 | +7.2% | +16.5% | +6.4% | +0.5% | +8.8% | +6.7% |
| Dec 15 | BofA Securities | Downgrade | Buy → Neutral | — | $29.79 | $29.39 | -1.3% | -4.6% | -7.9% | -0.9% | -7.3% | -5.8% |
| Dec 8 | Jefferies | Downgrade | Buy → Hold | — | $28.75 | $27.49 | -4.4% | -8.2% | -7.3% | -9.4% | -1.6% | +3.6% |
| Oct 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.31 | $22.02 | -1.3% | -0.2% | -6.8% | -17.7% | -20.7% | -14.4% |
| Sep 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.18 | $26.00 | -0.7% | -4.4% | -4.0% | -4.3% | -7.1% | -6.4% |
| Aug 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.43 | $23.37 | -0.3% | +1.2% | +0.3% | -1.1% | +0.1% | +1.1% |
| Aug 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $26.25 | $26.41 | +0.6% | -0.5% | -3.2% | -2.7% | -3.9% | -7.5% |
| Aug 9 | Credit Suisse | Maintains | Neutral → Neutral | — | $26.25 | $26.41 | +0.6% | -0.5% | -3.2% | -2.7% | -3.9% | -7.5% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $26.25 | $26.41 | +0.6% | -0.5% | -3.2% | -2.7% | -3.9% | -7.5% |
| May 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $35.85 | $35.58 | -0.8% | -1.9% | -7.0% | +0.4% | -5.6% | -2.5% |
| May 11 | Citigroup | Maintains | Buy → Buy | — | $35.85 | $35.58 | -0.8% | -1.9% | -7.0% | +0.4% | -5.6% | -2.5% |
| May 11 | Barclays | Maintains | Equal Weight → Equal Weight | — | $35.85 | $35.58 | -0.8% | -1.9% | -7.0% | +0.4% | -5.6% | -2.5% |
No insider trades available.
8-K · 2.02
!! High
Beam Therapeutics Inc. -- 8-K 2.02: Earnings Results
Beam Therapeutics reported Q1 2026 financial results on May 7, 2026, providing investors with updates on operational performance and cash position during the quarter.
May 7
8-K · 1.02
!! High
Beam Therapeutics Inc. -- 8-K 1.02: Material Agreement Terminated
Beam Therapeutics terminated a license agreement, which could impact its pipeline development and royalty obligations depending on the licensed technology's strategic importance to the company.
Mar 5
8-K · 1.01
!! High
Beam Therapeutics Inc. -- 8-K 1.01: Material Agreement
Beam Therapeutics secured a $500 million senior secured credit facility with an initial $100 million draw, providing crucial funding for operations and potential future clinical development needs.
Feb 24
8-K · 1.01
!! High
Beam Therapeutics Inc. -- 8-K 1.01: License Agreement
Beam Therapeutics holds sublicensed patent rights from Bio Palette covering Kobe University intellectual property, establishing a tiered licensing structure for the company's therapeutic development.
Feb 12
8-K · 5.02
!!! Very High
Beam Therapeutics Inc. -- 8-K 5.02: Executive Change
Carole Ho's resignation from Beam Therapeutics' board represents a minor leadership transition that investors should monitor for any broader governance changes or strategic shifts.
Feb 5
Data updated apr 24, 2026 9:06pm
· Source: massive.com